Trial Profile
Prospective Multicenter Randomized Openlabel Study to Evaluate the Benefit on Renal Function at 12months Post-transplantation of Immunosuppressive Treatment With Withdrawal of Calcineurin Inhibitor at 3months and Combining Mycophenolate Sodium-Everolimus Versus Tacrolimus-Everolimus, in Patients With de Novo Kidney Transplant
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mycophenolate sodium (Primary) ; Basiliximab; Everolimus; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms PROMeTe
- 30 Jul 2020 Status changed from active, no longer recruiting to completed.
- 11 Oct 2019 Planned End Date changed from 1 Dec 2020 to 30 May 2020.
- 11 Oct 2019 Status changed from recruiting to active, no longer recruiting.